Disclosed is the use of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule and at least one additional therapeutic agent selected from paclitaxel, carboplatin, oxaliplatin, doxorubicin, pemetrexed, etoposide, and a VEGF trap, for the manufacture of a medicament for treating cancer in a subject, wherein the medicament is formulated for administration of an effective amount of the FGFR1 ECD fusion molecule and the at least one additional therapeutic agent to the subject, and wherein administration of the FGFR1 ECD fusion molecule comprises an FGFR1 ECD comprising an amino acid sequence selected from SEQ ID NOs: 1 to 4 and a fusion partner, wherein administration of the FGFR1 ECD fusion molecule and the at least one additional therapeutic agent results in at least additive inhibition of tumour growth in a mouse xenograft model of the cancer, and wherein the sequences are as disclosed in the complete specification.
